Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693336 · ClinicalTrials.gov registry record · Phase 2
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
A Phase 2 study of Carcinoma, Non-Small-Cell Lung Cancer (NSCLC), sponsored by ToLymph.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT06693336: Recruiting Phase 2 study of Carcinoma, Non-Small-Cell Lung Cancer (NSCLC), sponsored by ToLymph.
NCT06693336 is a Phase 2 study of Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by ToLymph. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693336, a Phase 2 study of Carcinoma, Non-Small-Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by ToLymph.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
Primary Outcome
Treatment Emergent Adverse Events included laboratory assessments, physical examination findings, and vital signs.
Conditions Studied
Interventions
- DRUG SMS001
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Ontario
- Toronto General Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
What NCT06693336 shows while recruiting
NCT06693336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which SMS001 is the first listed.
NCT06693336 reports a single indexed study location in Minnesota, Ontario.
Frequently Asked Questions
What is clinical trial NCT06693336 about?
NCT06693336 is a clinical study titled "An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer". This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
What is the current status of trial NCT06693336?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2024-11-18. Estimated completion is 2026-12-30.
What conditions does trial NCT06693336 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT06693336?
The interventions under investigation include: SMS001 (DRUG).
Who is sponsoring clinical trial NCT06693336?
This trial is sponsored by ToLymph, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693336 being conducted?
This trial has 2 study locations across Minnesota, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06693336's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI